Patients in Cuba will have better access to therapy for lymphoma and rheumatoid arthritis

28.06.2018

Patients in Cuba will have better access to therapy for lymphoma and rheumatoid arthritis

The Ministry of Health of the Republic of Cuba (CECMED) has approved biosimilar rituximab developed by BIOCAD, a Russian biotech company. First supplies of the BIOCAD's rituximab are scheduled for late 2018, and market analysts expect it to make the treatment of lymphomas and rheumatoid arthritis more affordable for the Cuban patients.

More Category: Media release
Interleukin-17 Inhibitor Shows High Efficacy After One Year of Therapy in Psoriasis Patients

28.06.2018

Interleukin-17 Inhibitor Shows High Efficacy After One Year of Therapy in Psoriasis Patients

In March 2018, BIOCAD analyzed results from its Phase II study in which the original Russian IL-17 inhibitor proved highly effective in long-term therapy in patients with severe psoriasis. The drug also showed great results in the treatment of ankylosing spondylitis.

More Category: Media release
Russian infliximab biosimilar has been proved equivalent to Remicade® in international clinical trials

20.02.2018

Russian infliximab biosimilar has been proved equivalent to Remicade® in international clinical trials

BIOCAD has now completed the international clinical studies of infliximab biosimilar in ankylosing spondylitis and has finished the main phase of the international clinical study in rheumatoid arthritis. All studies were conducted in direct comparison with Remicade®. The therapeutic effects of the BIOCAD's infliximab biosimilar have been shown equivalent to the effects of the originator, and the safety profiles of two drugs were similar even in the long-term. BIOCAD ran its clinical studies of the infliximab biosimilar in compliance with the most recent international guidelines including the EMA's guidelines on non-clinical and clinical investigation of similar biological medicinal products containing monoclonal antibodies.

More Category: Media release
Cancer Research as Art: BIOCAD demonstrated the use of HeLa cells in oncology research

18.12.2017

Cancer Research as Art: BIOCAD demonstrated the use of HeLa cells in oncology research

unTOUCHABLE ART, Russia’s first sociocultural trip, was held in Saint-Petersburg in December. BIOCAD, a biotechnology company, demonstrated how “immortal” HeLa cells are used all over the world in oncology research and in development of anti-cancer drugs. The “IMMORTAL” installation devoted to the first ever cell line is part of a new science-art project that displays cancer research technologies.

More Category: Media release
BIOCAD launches the new manufacturing site in North Africa

30.11.2017

BIOCAD launches the new manufacturing site in North Africa

Russian biotechnology company BIOCAD and Moroccan pharmaceutical company Sothema Labs announced the launch of medicines derived using the technology provided by the Russian manufacturer into the North African market. The manufacturing of Russian biosimilars of rituximab and bevacizumab indicated for the treatment of cancer, approved in the first half of October 2017, will be based in Morocco. Besides Morocco, thеse biosimilars are planned to be marketed in Senegal, Gabon, and Côte d’Ivoire.

More Category: News
Russian biotechnology company BIOCAD prepares to enters the European market

30.10.2017

Russian biotechnology company BIOCAD prepares to enters the European market

The largest Russian biotechnology company BIOCAD plans to enter the European market with oncological and autoimmune medicines. So far, there are seven molecules in the European portfolio of BIOCAD. This are innovative and biosimilar products, which could be used in treatment of melanoma, breast, stomach, kidney and lung cancer, rheumatoid arthritis, psoriasis and multiple sclerosis.

More Category: Media release
BIOCAD’s rituximab biosimilar to receive MA soon in India

04.07.2017

BIOCAD’s rituximab biosimilar to receive MA soon in India

 On 20th of June 2017, the Central Drugs Standard Control Organization (CDSCO) has recommended Acellbia, the first rituximab biosimilar made in Russia, for approval in India.  In August 2017, BIOCAD will receive permanent market authorization in India, which represents a strategic milestone for BIOCAD’s international expansion.

More Category: Media release
BIOCAD registered the first rituximab biosimilar in Bolivia and Honduras

06.06.2017

BIOCAD registered the first rituximab biosimilar in Bolivia and Honduras

In 2017, BIOCAD obtained a marketing authorization for its rituximab biosimilar in Bolivia and Honduras under the trade name USMAL. First shipments will start in the beginning of the third quarter of 2017. BIOCAD will be able to supply as much rituximab as needed for Bolivian and Honduran patients. Considering competitive price of the Russian biosimilar, estimated drug availability will double.

More Category: News
BIOCAD keeps on supplying its medicine for blood cancer treatment in Vietnam

30.03.2017

BIOCAD keeps on supplying its medicine for blood cancer treatment in Vietnam

In March BIOCAD biotechnology company was granted access to supply highly demanded medicine - rituximab biosimilar to Vietnam for a second time. It means that BIOCAD partners will continue to supply local hospitals with the Russian product and patients will get access to affordable and effective treatment in Vietnam.     

More Category: Media release
Innovative Russian drug product mobilizes human immune system to fight cancer

06.02.2017

Innovative Russian drug product mobilizes human immune system to fight cancer

Revolutionary Russian anti-cancer anti-PD1 medicine candidate has successfully ended pre-clinical animal trials, i.e. on primates. So far the product has demonstrated higher efficacy than the only two approved medicines acting  against the same therapeutic target – pembrolizumab from Merck and nivolumab from BMS. 

BIOCAD is now preparing for the first international multi-center clinical trials. Patients in Russia will be among the first to get access to the new generation therapy.  The medicine is expected to be available to patients as early as in 2018 or 2019.

More Category: Media release
Advanced rheumatoid arthritis medicine developed in Russia

11.07.2016

Advanced rheumatoid arthritis medicine developed in Russia

Biotechnological company BIOCAD has developed innovative medicine for treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and other autoimmune diseases.

More Category: Media release
Patients received no cancer medicines because of unfair competition from Hoffmann-La Roche in Sri Lanka

11.07.2016

Patients received no cancer medicines because of unfair competition from Hoffmann-La Roche in Sri Lanka

Due to unsubstantiated, frivolous claims by Swiss drug-maker F. Hoffmann-La Roche, Ltd. in a desperate attempt to cease the distribution of the Russian-made anti-tumor biosimilar products, as well as seeking to revoke BIOCAD’s product market authorization in Sri Lanka, cancer patients in this South-East country haven’t received the essential anti-cancer drugs trastuzumab and bevacizumab in time. After a series of hearings, in late June the Court of Appeals of Sri Lanka finally dismissed the claims from the Swiss originator and terminated interim in relief

More Category: Media release
BIOCAD announces the first trastuzumab biosimilar approved by the Ministry of Health of the Russian Federation

11.02.2016

BIOCAD announces the first trastuzumab biosimilar approved by the Ministry of Health of the Russian Federation

The trastuzumab biosimilar, to be marketed under the trade name HERtiCAD™, is the first trastuzumab biosimilar to receive authorization from the Russian regulatory body

More Category: Media release
Russia’s only project to supply local high-tech anti-cancer drugs abroad  continues with the first shipment to Vietnam

11.02.2016

Russia’s only project to supply local high-tech anti-cancer drugs abroad continues with the first shipment to Vietnam

Russian biopharmaceutical company BIOCAD is the first company in the country to launch a 150-million-dollar effort to supply therapeutic products based on monoclonal antibodies to several countries outside Russia. In the end of December BIOCAD made its first shipment to Vietnam.

More Category: Media release
BIOCAD - World Leader in Biosimilar Rituximab Sales

22.10.2015

BIOCAD - World Leader in Biosimilar Rituximab Sales

Biopharmaceutical company BIOCAD is now the world leader in sales of biosimilar rituximab. Company revenue from sales of Acellbia™, exceeded $155 million in 2014, representing more than 80% of global sales of non-originator rituximab biologicals.

More Category: Media release
Supplies of Russian anti-cancer drug into Egypt will amount to $42.7 million

08.09.2015

Supplies of Russian anti-cancer drug into Egypt will amount to $42.7 million

On September 3, 2015 in St. Petersburg, Russia, an agreement was signed between a Russian innovative biotech company BIOCAD and the Egyptian company MED. PHARMA GROUP regarding supplies of anti-cancer drug Rituximab into Egypt.

More Category: News
200 million rubles in creation of new R&D

12.08.2015

200 million rubles in creation of new R&D

The biotechnological corporation BIOCAD has invested over 200 million rubles in creation of new R&D center in St. Petersburg area.

More Category: Media release
Nobel laureate James Watson visited BIOCAD

23.06.2015

Nobel laureate James Watson visited BIOCAD

James Watson, who won the 1962 Nobel Prize in Biology and Medicine for the discovery of three-dimensional molecular structure of DNA, on June 20 visited the laboratories of the innovative biotech company BIOCAD.

More Category: News